

# Lymphome Plasmablastique

# Présentation

Table 1. Most common sites of involvement in PBL (literature review from 1997 to 2014)



Sites of involvement	Total Cases		HIV-positive		HIV-negative	
	No.	%	No.	%	No.	%
Oral	260	44	178	48	65	40
Gastrointestinal	83	14	43	12	34	21
Lymph nodes	43	7	17	5	14	9
Skin	41	7	22	6	10	7
Bone	26	4	19	5	4	2
Genitourinary	23	4	12	3	6	4
Nose	18	3	11	3	6	4
Central nervous system	17	3	12	3	4	2
Liver	11	2	8	2	2	1
Lung	11	2	9	2	1	0.6
Orbit	10	2	8	2	2	1
Spleen	5	0.8	4	1	1	0.6
Skull	5	0.8	4	1	1	0.6
Retroperitoneum	4	0.7	1	0.2	3	2
Breast	3	0.5	1	0.2	1	0.6
Larynx	2	0.3	2	0.5	—	
Gallbladder	2	0.3	2	0.5	—	
Choroid	1	0.1	—		1	0.6
Heart	1	0.1	—		1	0.6
Parotid	1	0.1	—		1	0.6
Muscle	1	0.1	—		1	0.6
Not specified	22	4	16	4	6	4
Total	590		369		164	

# Immunophenotype

Immunophenotype	
CD10	20%
CD20	Low
CD30	Subset
CD45	Low
CD56	25%
CD79a	Common
CD138	90%
ALK-1	0%
BCL-2	Uncommon
BCL-6	Negative
EMA	Common
HHV-8	0%
IRF-4/MUM-1	~100%
EBV LMP-1	Uncommon
EBNA-2	Negative
EBV latency pattern	Type I

Cytoplasm Ig	Common
MIB-1/Ki-67	High
PAX-5	Negative
MYC	~50%
TP53	~50%
Molecular testing	
BCL-2 GR	Negative
BCL-6 GR	Negative
EBER	66%
IgH GR	Monoclonal
MYC GR/ amplifications	57%
TCR GR	Polyclonal

# Survie



# Traitement

- Pas de traitement standard
- CHOP pas bon
- DA-EPOCH mieux?
- DA-EPOCH+ Bortezomib: 3 cas...
- Prophylaxie méningée.
- Notre attitude:
  - Protocole type Burkitt (LMB)
  - Autogreffe en 1<sup>ère</sup> réponse si faisable
- Brentuximab Vedotin (anti CD30) 3 cas




Figure 1. Survival after transplantation (10 patients).




Figure 2. Survival from study entry (20 patients).